贝达喹啉-普托马尼-莫西沙星-吡嗪酰胺方案治疗药物敏感和耐药肺结核:一项2c期、开放标签、多中心、部分随机对照试验
SimpliciTB试验在8国26中心纳入455例肺结核患者,比较4个月贝达喹啉-普托马尼-莫西沙星-吡嗪酰胺(BPaMZ)与6个月HRZE方案治疗药物敏感(DS)结核,并评估6个月BPaMZ治疗耐药(DR)结核。4个月BPaMZ达到主要终点(第8周培养转阴率84% vs 47%,HR 2.93),但未达到关键次要终点非劣效界值,因肝毒性相关退出较多。
要点
- 4个月BPaMZ组第8周培养转阴率84%(122/145),HRZE组47%(70/148),HR 2.93(95%CI 2.17-3.96;p<0.0001)。
- 4个月BPaMZ中位培养转阴时间6周(IQR 4-8),HRZE组11周(6-12)。
- 4个月BPaMZ未达到关键次要终点非劣效界值,因不良事件退出率较高,主要为肝毒性事件。
核心结论
- 对于DS-TB,4个月BPaMZ成功达到主要疗效终点(痰培养转阴)。
- 该方案因不良事件导致治疗退出而未达到关键次要疗效终点。
- 本研究证明了BPaMZ方案对DS-TB和DR-TB具有缩短疗程的疗效潜力,并为广泛用于识别此类方案的鼠模型提供了临床验证。
- 研究强调新型缩短疗程方案需在低资源高负担环境下具有可接受的毒性和耐受性且监测需求最少。
- 4个月BPaMZ增加不可预测的严重肝脏不良事件风险,在结核高负担且密切监测肝功能基础设施有限的地区将成为实施的重大障碍。
研究设计与样本
- SimpliciTB为部分随机、2c期、开放标签临床试验,在8个国家26个中心招募受试者。
- 纳入年龄≥18岁、痰涂片抗酸杆菌阳性的肺结核患者;DS-TB对利福平和异烟肼敏感,DR-TB对利福平和/或异烟肼耐药。
- DS-TB患者按1:1比例随机分配,按HIV状态和胸片空洞分层,采用固定区组大小为4的平衡区组随机化。
- 主要疗效终点为至第8周痰培养转阴的时间;关键次要终点为第52周的不良结局;关键次要结局的非劣效界值为12%。
- 疗效分析人群包含至少接受一剂药物且有疗效数据且无重大方案违背的患者;安全性人群包含至少接受一剂药物的患者。
主要发现
- 2018年7月30日至2020年3月2日期间,455例受试者入组并至少接受一剂研究治疗;324例(71%)为男性,131例(29%)为女性。
- 303例DS-TB患者随机分配至4个月BPaMZ组(n=150)或HRZE组(n=153)。
- 改良意向治疗(mITT)分析中,第8周时4个月BPaMZ组145例中122例(84%)培养转阴,HRZE组148例中70例(47%)培养转阴,更早转阴的风险比为2.93(95%CI 2.17-3.96;p<0.0001)。
- 4个月BPaMZ组中位培养转阴时间(TTN)为6周(IQR 4-8),HRZE组为11周(6-12)。
- 接受6个月BPaMZ的DR-TB患者(n=152)中86%在第8周达到培养转阴,中位TTN为5周(IQR 3-7)。
关键数值与推荐
- DS-TB主要疗效终点:第8周培养转阴率4个月BPaMZ组84%(122/145)vs HRZE组47%(70/148),HR 2.93(95%CI 2.17-3.96;p<0.0001)。
- DS-TB关键次要终点:第52周良好结局4个月BPaMZ组83%(120/144)vs HRZE组93%(134/144),非劣效界值12%,mITT人群未达到。
- DR-TB:6个月BPaMZ组第8周培养转阴率86%(n=152),中位TTN 5周(IQR 3-7);第52周良好结局83%(111/133)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 4个月BPaMZ因不良事件导致治疗退出而未达到关键次要疗效终点。
- 4个月BPaMZ增加不可预测的严重肝脏不良事件风险,在结核高负担且密切监测肝功能基础设施有限的地区将成为实施的重大障碍。
- 未来研究应聚焦于共同改进临床前和早期临床安全性问题的检测与缓解,并进一步优化更短疗程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current tuberculosis (TB) drug development pipeline is being re-populated with candidates, including nitroimidazoles such as pretomanid, that exhibit a potential to shorten TB therapy by exerting a bactericidal effect on non-replicating bacilli. Based on results from preclinical and early clinical studies, a four-drug combination of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide (BPaMZ) regimen was identified with treatment-shortening potential for both drug-susceptible (DS) and drug-resistant (DR) TB. This trial aimed to determine the safety and efficacy of BPaMZ. We compared 4 months of BPaMZ to the standard 6 months of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE) in DS-TB. 6 months of BPaMZ was assessed in DR-TB. METHODS: SimpliciTB was a partially randomised, phase 2c, open-label, clinical trial, recruiting participants at 26 sites in eight countries. Participants aged 18 years or older with pulmonary TB who were sputum smear positive for acid-fast bacilli were eligible for enrolment. Participants with DS-TB had Mycobacterium tuberculosis with sensitivity to rifampicin and isoniazid. Participants with DR-TB had M tuberculosis with resistance to rifampicin, isoniazid, or both. Participants with DS-TB were randomly allocated in a 1:1 ratio, stratified by HIV status and cavitation on chest radiograph, using balanced block randomisation with a fixed block size of four. The primary efficacy endpoint was time to sputum culture-negative status by 8 weeks; the key secondary endpoint was unfavourable outcome at week 52. A non-inferiority margin of 12% was chosen for the key secondary outcome. Safety and tolerability outcomes are presented as descriptive analyses. The efficacy analysis population contained patients who received at least one dose of medication and who had efficacy data available and had no major protocol violations. The safety population contained patients who received at least one dose of medication. This study is registered with ClinicalTrials.gov (NCT03338621) and is completed. FINDINGS: Between July 30, 2018, and March 2, 2020, 455 participants were enrolled and received at least one dose of study treatment. 324 (71%) participants were male and 131 (29%) participants were female. 303 participants with DS-TB were randomly assigned to 4 months of BPaMZ (n=150) or HRZE (n=153). In a modified intention-to-treat (mITT) analysis, by week 8, 122 (84%) of 145 and 70 (47%) of 148 participants were culture-negative on 4 months of BPaMZ and HRZE, respectively, with a hazard ratio for earlier negative status of 2·93 (95% CI 2·17-3·96; p<0·0001). Median time to negative culture (TTN) was 6 weeks (IQR 4-8) on 4 months of BPaMZ and 11 weeks (6-12) on HRZE. 86% of participants with DR-TB receiving 6 months of BPaMZ (n=152) reached culture-negative status by week 8, with a median TTN of 5 weeks (IQR 3-7). At week 52, 120 (83%) of 144, 134 (93%) of 144, and 111 (83%) of 133 on 4 months of BPaMZ, HRZE, and 6 months of BPaMZ had favourable outcomes, respectively. Despite bacteriological efficacy, 4 months of BPaMZ did not meet the non-inferiority margin for the key secondary endpoint in the pre-defined mITT population due to higher withdrawal rates for adverse hepatic events. Non-inferiority was demonstrated in the per-protocol population confirming the effect of withdrawals with 4 months of BPaMZ. At least one liver-related treatment-emergent adverse effect (TEAE) occurred among 45 (30%) participants on 4 months of BPaMZ, 38 (25%) on HRZE, and 33 (22%) on 6 months of BPaMZ. Serious liver-related TEAEs were reported by 20 participants overall; 11 (7%) among those on 4 months of BPaMZ, one (1%) on HRZE, and eight (5%) on 6 months of BPaMZ. The most common reasons for discontinuation of trial treatment were hepatotoxicity (ten participants [2%]), increased hepatic enzymes (nine participants [2%]), QTcF prolongation (three participants [1%]), and hypersensitivity (two participants [<1%]). INTERPRETATION: For DS-TB, BPaMZ successfully met the primary efficacy endpoint of sputum culture conversion. The regimen did not meet the key secondary efficacy endpoint due to adverse events resulting in treatment withdrawal. Our study demonstrated the potential for treatment-shortening efficacy of the BPaMZ regimen for DS-TB and DR-TB, providing clinical validation of a murine model widely used to identify such regimens. It also highlights that novel, treatment-shortening TB treatment regimens require an acceptable toxicity and tolerability profile with minimal monitoring in low-resource and high-burden settings. The increased risk of unpredictable severe hepatic adverse events with 4 months of BPaMZ would be a considerable obstacle to implementation of this regimen in settings with high burdens of TB with limited infrastructure for close surveillance of liver biochemistry. Future research should focus on improving the preclinical and early clinical detection and mitigation of safety issues together and further efforts to optimise shorter treatments. FUNDING: TB Alliance.
引用
- Cevik M, Thompson LC, Upton C, et al. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024. PMID: 38768617. doi:10.1016/S1473-3099(24)00223-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。